Search

Your search keyword '"S Yusu"' showing total 4 results
Start Over Author "S Yusu" Topic atrial fibrillation
4 results on '"S Yusu"'

1. Quantitative assessment of cibenzoline administration for vagally mediated paroxysmal atrial fibrillation using frequency-domain heart rate variability analysis.

Author

Miyakoshi M, Ikeda T, Miwa Y, Sakaki K, Ishiguro H, Abe A, Tsukada T, Mera H, Yusu S, and Yoshino H

Subjects
Cholinergic Antagonists therapeutic use, Disopyramide therapeutic use, Female, Heart Rate, Humans, Male, Middle Aged, Treatment Outcome, Anti-Arrhythmia Agents therapeutic use, Atrial Fibrillation drug therapy, Electrocardiography, Ambulatory, Imidazoles therapeutic use
Abstract

Background: Cibenzoline (CBZ), a class I antiarrhythmic drug, has been widely used to maintain sinus rhythm in patients with paroxysmal atrial fibrillation (P-AF). This agent has an anticholinergic action and will become the drug of first choice for vagally mediated P-AF. We assessed its efficacy quantitatively by analyzing the frequency-domain heart rate variability (FD-HRV) of the Holter electrocardiogram (ECG) in patients with vagal P-AF., Methods: We enrolled 65 consecutive patients with vagal P-AF, but 31 patients were excluded because of the occurrence of significant arrhythmias during the 24-h Holter recordings. Accordingly, CBZ was administered to the remaining 34 patients. After administration, a Holter ECG recording was made again. High frequency (HF) components, i.e., vagal tone index, on the FD-HRV analysis from 00:00 h to 06:00 h were used for assessment. In 14 patients, the treatment was changed to disopyramide (DSP) and the same analyses were performed., Results: In two patients, the FD-HRV analysis was not utilized after administration. Finally, 32 patients were available for evaluation. CBZ was considered effective for vagal P-AF in 24 patients (75%). After administration, the HF component levels decreased (1589+/-795 ms(2) vs. 850+/-524 ms(2), p<0.0001). Comparison of the pre-administration HF component levels between the CBZ-responsive group and the CBZ-non-responsive group showed higher levels in the CBZ-responsive group (1766+/-758 ms(2) vs. 1058+/-690 ms(2), p=0.026). Although no significant difference in the reduction of the HF component levels was found between CBZ and DSP, DSP had anticholinergic side effects in two patients (14%)., Conclusions: In vagal P-AF patients, larger HF components on the FD-HRV analysis could be a hallmark of the antiarrhythmic action of CBZ. The reduction in the HF component levels after drug administration is useful for a quantitative assessment of anticholinergic action.

Published
2009
Full Text
View/download PDF

2. Antiarrhythmic effect of bisoprolol, a highly selective beta1-blocker, in patients with paroxysmal atrial fibrillation.

Author

Ishiguro H, Ikeda T, Abe A, Tsukada T, Mera H, Nakamura K, Yusu S, and Yoshino H

Subjects
Aged, Atrial Fibrillation diagnosis, Circadian Rhythm, Electrocardiography, Ambulatory, Female, Humans, Male, Middle Aged, Quality of Life, Treatment Outcome, Adrenergic beta-Antagonists administration & dosage, Anti-Arrhythmia Agents administration & dosage, Atrial Fibrillation drug therapy, Bisoprolol administration & dosage, Receptors, Adrenergic, beta-1 drug effects
Abstract

In the treatment of arrhythmia, beta-blockers are mainly used to regulate the heart rate. However, beta-blockers are also known as drugs with an antiarrhythmic effect due to the suppression of sympathetic activity. We evaluated the antiarrhythmic effects of a highly selective beta(1)-blocker, bisoprolol, in patients with diurnal paroxysmal atrial fibrillation (P-AF). A total of 136 patients with symptomatic diurnal P-AF were enrolled. Patients were divided into a diurnal-specific P-AF group and a diurnal & nocturnal P-AF group, as well as into a bisoprolol single use group and a combined use group with an antiarrhythmic drug. The effects of bisoprolol were evaluated in 3 categories: subjective symptom improvement, quality of life (QOL) improvement, and elimination of P-AF episode in Holter electrocardiograms (ECGs). For patients with effective treatment, a long-term effect up to 24 months was evaluated. Five patients (3.7%) discontinued bisoprolol due to side effects. Following administration of bisoprolol, 109 patients (80%) experienced subjective symptom improvement, 103 patients (76%) experienced QOL improvement, and elimination of P-AF episodes in ECGs was observed in 84 patients (62%). The elimination rate of P-AF episodes in ECGs was higher in the diurnal P-AF group than in the diurnal & nocturnal P-AF group (P=0.042). There was no significant difference between the bisoprolol single use group and the combined use group. A long-term suppressive effect by bisoprolol was observed in 70 of 83 patients (84%). The results demonstrate that bisoprolol has an antiarrhythmic effect against sympathetic diurnal P-AF, improving subjective symptoms and QOL and eliminating P-AF episodes in ECGs.

Published
2008
Full Text
View/download PDF

3. Impact of Blood Pressure Visit‐to‐Visit Variability on Adverse Events in Patients With Nonvalvular Atrial Fibrillation: Subanalysis of the J‐RHYTHM Registry

Author

Eitaro Kodani, Hiroshi Inoue, Hirotsugu Atarashi, Ken Okumura, Takeshi Yamashita, Toshiaki Otsuka, Hideki Origasa, H Inoue, K Okumura, H Atarashi, T Yamashita, M Sakurai, Y Kawamura, I Kubota, Y Kaneko, K Matsumoto, S Ogawa, Y Aizawa, I Kodama, E Watanabe, Y Koretsune, Y Okuyama, A Shimizu, O Igawa, S Bando, M Fukatani, T Saikawa, A Chishaki, H Origasa, N Kato, K. Kanda, J Kato, H Obata, M Aoki, H. Honda, Y Konta, T Hatayama, Y Abe, K Terata, T Yagi, A Ishida, T Komatsu, H Tachibana, H Suzuki, Y Kamiyama, T Watanabe, M Oguma, M Itoh, O Hirono, Y Tsunoda, K Ikeda, T Kanaya, K Sakurai, H Sukekawa, S Nakada, T Itoh, S Tange, M. Manita, M Ohta, H Eguma, R Kato, Y Endo, T Ogino, M Yamazaki, H Kanki, M Uchida, S Miyanaga, K Shibayama, N Toratani, T Kojima, M Ichikawa, M Saito, Y Umeda, T Sawanobori, H Sohara, S Okubo, T Okubo, T. Tokunaga, O Kuboyama, H Ito, Y Kitahara, K Sagara, T Satoh, E Kodani, K Sugi, Y Kobayashi, Y Higashi, T Katoh, Y Hirayama, N Matsumoto, M Takano, T Ikeda, S Yusu, S Niwano, Y Nakazato, Y Kawano, M Sumiyoshi, N Hagiwara, K Murasaki, H Mitamura, S Nakagawa, K Okishige, K Azegami, H Aoyagi, K Sugiyama, M Nishizaki, N Yamawake, I Watanabe, K Ohkubo, H Sakurada, S Fukamizu, M Suzuki, W Nagahori, T Nakamura, Y Murakawa, N Hayami, K Yoshioka, M Amino, K Hirao, A Yagishita, K Ajiki, K Fujiu, Y Imai, A Yamashina, T Ishiyama, M Sakabe, K Nishida, H Asanoi, H Ueno, null Lee, Y Mitsuke, H Furushima, K Ebe, M Tagawa, M Sato, M. Morikawa, K Yamashiro, K Takami, T Ozawa, M Watarai, M Yamauchi, H Kamiya, H. Hirayama, Y. Yoshida, T Murohara, Y Inden, H Osanai, N Ohte, T Goto, I Morishima, T Yamamoto, E Fujii, M Senga, H. Hayashi, T Urushida, Y Takada, N Tsuboi, T Noda, T Hirose, T Onodera, S Kageyama, T Osaka, T. Tomita, K Shimada, M Nomura, H Izawa, A Sugiura, T Arakawa, K. Kimura, T Mine, T Makita, H Mizuno, A Kobori, T Haruna, M Takagi, N Tanaka, H Shimizu, T Kurita, K Motoki, N Takeda, Y Kijima, M Ito, A Nakata, Y Ueda, A Hirata, S Kamakura, K Satomi, Y. Yamada, Y. Yoshiga, H Ogawa, M Kimura, T Hayano, T Kinbara, H Tatsuno, M Harada, K. Kusano, M Adachi, A Yano, M Sawaguchi, J Yamasaki, T Matsuura, Y Tanaka, H Moritani, T Maki, S Okada, M Takechi, T Hamada, A Nishikado, Y Takagi, I Matsumoto, T Soeki, Y Doi, M Okawa, H Seo, S Kitamura, K Yamamoto, M Akizawa, N Kaname, S Ando, S Narita, T Inou, Y Fukuizumi, K Saku, M Ogawa, Y Urabe, M Ikeuchi, S Harada, H Yamabe, Y Imamura, Y. Yamanouchi, K Sadamatsu, K Yoshida, T Kubota, N Takahashi, N Makino, Y Higuchi, T Ooie, T Iwao, K. Kitamura, T Imamura, K Maemura, N Komiya, M Hayano, H Yoshida, and K. Kumagai

Subjects
Male, medicine.medical_specialty, Hemorrhage, Risk Assessment, Rhythm, Japan, Risk Factors, Cause of Death, Thromboembolism, Internal medicine, Atrial Fibrillation, Ambulatory Care, medicine, Humans, Arrhythmia and Electrophysiology, In patient, Registries, Risk factor, Adverse effect, Original Research, Aged, Analysis of Variance, variability, Clinical events, business.industry, blood pressure, Anticoagulants, Blood Pressure Determination, Atrial fibrillation, medicine.disease, Blood pressure, major hemorrhage, Hypertension, Cardiology, Female, Warfarin, Cardiology and Cardiovascular Medicine, business, Platelet Aggregation Inhibitors
Abstract

Background Blood pressure (BP) variability has reportedly been a risk factor for various clinical events. To clarify the influence of BP visit‐to‐visit variability on adverse events in patients with nonvalvular atrial fibrillation, a post hoc analysis of the J‐RHYTHM Registry was performed. Methods and Results Of 7406 outpatients with nonvalvular atrial fibrillation from 158 institutions, 7226 (age, 69.7±9.9 years; men, 70.7%), in whom BP was measured 4 times or more (14.6±5.0 times) during the 2‐year follow‐up period or until occurrence of an event, constituted the study group. SD and coefficient of variation of BP values were calculated as BP variability. Thromboembolism, major hemorrhage, and all‐cause death occurred in 110 (1.5%), 121 (1.7%), and 168 (2.3%) patients, respectively. When patients were divided into quartiles of systolic BP‐SD (P =0.015 for thromboembolism; HR, 2.60, 95% CI, 1.36–4.97, P =0.004 for major hemorrhage; and HR, 1.85, 95% CI, 1.11–3.07, P =0.018 for all‐cause death) after adjusting for components of the CHA 2 DS 2 ‐VASc score, warfarin and antiplatelet use, atrial fibrillation type, BP measurement times, and others. These findings were consistent when BP‐coefficient of variation was used instead of BP‐SD. Conclusions Systolic BP visit‐to‐visit variability was significantly associated with all adverse events in patients with nonvalvular atrial fibrillation. Further studies are needed to clarify the causality between BP variability and adverse outcomes in patients with nonvalvular atrial fibrillation. Registration URL: https://www.umin.ac.jp/ctr/ ; Unique Identifier: UMIN000001569.

Published
2021
Full Text
View/download PDF

4. Impact of Blood Pressure Control on Thromboembolism and Major Hemorrhage in Patients With Nonvalvular Atrial Fibrillation: A Subanalysis of the J‐RHYTHM Registry

Author

Eitaro Kodani, Hirotsugu Atarashi, Hiroshi Inoue, Ken Okumura, Takeshi Yamashita, Toshiaki Otsuka, Hirofumi Tomita, Hideki Origasa, M. Sakurai, Y. Kawamura, I. Kubota, Y. Kaneko, K. Matsumoto, S. Ogawa, Y. Aizawa, I. Kodama, E. Watanabe, Y. Koretsune, Y. Okuyama, A. Shimizu, O. Igawa, S. Bando, M. Fukatani, T. Saikawa, A. Chishaki, N. Kato, K. Kanda, J. Kato, H. Obata, M. Aoki, H. Honda, Y. Konta, T. Hatayama, Y. Abe, K. Terata, T. Yagi, A. Ishida, T. Komatsu, H. Tachibana, H. Suzuki, Y. Kamiyama, T. Watanabe, M. Oguma, M. Itoh, O. Hirono, Y. Tsunoda, K. Ikeda, T. Kanaya, K. Sakurai, H. Sukekawa, S. Nakada, T. Itoh, S. Tange, M. Manita, M. Ohta, H. Eguma, R. Kato, Y. Endo, T. Ogino, M. Yamazaki, H. Kanki, M. Uchida, S. Miyanaga, K. Shibayama, N. Toratani, T. Kojima, M. Ichikawa, M. Saito, Y. Umeda, T. Sawanobori, H. Sohara, S. Okubo, T. Okubo, T. Tokunaga, O. Kuboyama, H. Ito, Y. Kitahara, K. Sagara, T. Satoh, K. Sugi, Y. Kobayashi, Y. Higashi, T. Katoh, Y. Hirayama, N. Matsumoto, M. Takano, T. Ikeda, S. Yusu, S. Niwano, Y. Nakazato, Y. Kawano, M. Sumiyoshi, N. Hagiwara, K. Murasaki, H. Mitamura, S. Nakagawa, K. Okishige, K. Azegami, H. Aoyagi, K. Sugiyama, M. Nishizaki, N. Yamawake, I. Watanabe, K. Ohkubo, H. Sakurada, S. Fukamizu, M. Suzuki, W. Nagahori, T. Nakamura, Y. Murakawa, N. Hayami, K. Yoshioka, M. Amino, K. Hirao, A. Yagishita, K. Ajiki, K. Fujiu, Y. Imai, A. Yamashina, T. Ishiyama, M. Sakabe, K. Nishida, H. Asanoi, H. Ueno, J. D. Lee, Y. Mitsuke, H. Furushima, K. Ebe, M. Tagawa, M. Sato, M. Morikawa, K. Yamashiro, K. Takami, T. Ozawa, M. Watarai, M. Yamauchi, H. Kamiya, H. Hirayama, Y. Yoshida, T. Murohara, Y. Inden, H. Osanai, N. Ohte, T. Goto, I. Morishima, T. Yamamoto, E. Fujii, M. Senga, H. Hayashi, T. Urushida, Y. Takada, N. Tsuboi, T. Noda, T. Hirose, T. Onodera, S. Kageyama, T. Osaka, T. Tomita, K. Shimada, M. Nomura, H. Izawa, A. Sugiura, T. Arakawa, K. Kimura, T. Mine, T. Makita, H. Mizuno, A. Kobori, T. Haruna, M. Takagi, N. Tanaka, H. Shimizu, T. Kurita, K. Motoki, N. Takeda, Y. Kijima, M. Ito, A. Nakata, Y. Ueda, A. Hirata, S. Kamakura, K. Satomi, Y. Yamada, Y. Yoshiga, H. Ogawa, M. Kimura, T. Hayano, T. Kinbara, H. Tatsuno, M. Harada, K. F. Kusano, M. Adachi, A. Yano, M. Sawaguchi, J. Yamasaki, T. Matsuura, Y. Tanaka, H. Moritani, T. Maki, S. Okada, M. Takechi, T. Hamada, A. Nishikado, Y. Takagi, I. Matsumoto, T. Soeki, Y. Doi, M. Okawa, H. Seo, S. Kitamura, K. Yamamoto, M. Akizawa, N. Kaname, S. Ando, S. Narita, T. Inou, Y. Fukuizumi, K. Saku, M. Ogawa, Y. Urabe, M. Ikeuchi, S. Harada, H. Yamabe, Y. Imamura, Y. Yamanouchi, K. Sadamatsu, K. Yoshida, T. Kubota, N. Takahashi, N. Makino, Y. Higuchi, T. Ooie, T. Iwao, K. Kitamura, T. Imamura, K. Maemura, N. Komiya, M. Hayano, H. Yoshida, and K. Kumagai

Subjects
Male, medicine.medical_specialty, lcsh:Diseases of the circulatory (Cardiovascular) system, hypertension, medicine.drug_class, Diastole, Hemorrhage, 030204 cardiovascular system & hematology, 03 medical and health sciences, 0302 clinical medicine, Japan, Risk Factors, Internal medicine, Odds Ratio, Medicine, Humans, Arrhythmia and Electrophysiology, atrial fibrillation, 030212 general & internal medicine, Prospective Studies, Registries, Risk factor, Antihypertensive drug, anticoagulation, Antihypertensive Agents, Original Research, Ischemic Stroke, Intracranial Hemorrhage, Aged, Proportional Hazards Models, business.industry, Hazard ratio, Warfarin, blood pressure, Atrial fibrillation, Odds ratio, Middle Aged, thromboembolism, medicine.disease, Blood pressure, High Blood Pressure, lcsh:RC666-701, Cardiology, Female, Cardiology and Cardiovascular Medicine, business, medicine.drug
Abstract

Background To clarify the influence of hypertension and blood pressure ( BP ) control on thromboembolism and major hemorrhage in patients with nonvalvular atrial fibrillation, a post hoc analysis of the J‐ RHYTHM Registry was performed. Methods and Results A consecutive series of outpatients with atrial fibrillation was enrolled from 158 institutions. Of 7937 patients, 7406 with nonvalvular atrial fibrillation (70.8% men, 69.8±10.0 years) were followed for 2 years or until an event occurred. Hypertension was defined as a systolic BP ≥140 mm Hg, a diastolic BP ≥90 mm Hg, a history of hypertension, and/or antihypertensive drug use. Hypertension was an independent risk factor for major hemorrhage (hazard ratio 1.52, 95% CI 1.05–2.21, P =0.027) but not for thromboembolism (hazard ratio 1.05, 95% CI 0.73–1.52, P =0.787). When patients were divided into quartiles according to their systolic BP at the time closest to the event or at the end of follow‐up (Q1, CI 1.75–4.74, P CI 1.02–2.53, P =0.041) after adjustment for components of CHA 2 DS 2 ‐ VAS c score, warfarin use, and antiplatelet use. A systolic BP of ≥136 mm Hg was an independent risk factor for thromboembolism and major hemorrhage. Conclusions BP control appears to be more important than a history of hypertension and baseline BP values at preventing thromboembolism and major hemorrhage in patients with nonvalvular atrial fibrillation. Clinical Trial Registration URL : http://www.umin.ac.jp/ctr . Unique identifier: UMIN 000001569.

Published
2016

Catalog

Books, media, physical & digital resources
See catalog results